Biovie Inc (BIVI)

$1.74

+0.06

(+3.57%)▲

Market is closed - opens 8 PM, 05 Dec 2023

Insights on Biovie Inc

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 73.8% return, outperforming this stock by 143.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 18.7% return, outperforming this stock by 99.7%

Performance

  • $1.63
    $1.80
    $1.74
    downward going graph

    6.55%

    Downside

    Day's Volatility :9.67%

    Upside

    3.33%

    downward going graph
  • $1.74
    $14.38
    $1.74
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :87.9%

    Upside

    87.9%

    downward going graph

Returns

PeriodBiovie IncSector (Health Care)Index (Russel 2000)
3 Months
-45.1%
-1.3%
0.0%
6 Months
-69.95%
1.2%
0.0%
1 Year
-67.75%
-5.7%
-6.5%
3 Years
-80.97%
17.1%
-6.5%

Highlights

Market Capitalization
188.1M
Book Value
$0.21
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.46
Wall Street Target Price
11.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-126.35%
Return On Equity TTM
-748.41%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-46.9M
Diluted Eps TTM
-1.46
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.76
EPS Estimate Next Year
-1.44
EPS Estimate Current Quarter
-0.31
EPS Estimate Next Quarter
-0.24

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Biovie Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 560.92%

Current $1.74
Target $11.50

Technicals Summary

Sell

Neutral

Buy

Biovie Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biovie Inc
Biovie Inc
-58.72%
-69.95%
-67.75%
-80.97%
-83.18%
Moderna, Inc.
Moderna, Inc.
10.77%
-38.07%
-54.62%
-47.66%
329.19%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-2.11%
8.61%
7.86%
65.47%
118.58%
Novo Nordisk A/s
Novo Nordisk A/s
-0.67%
27.21%
58.01%
196.12%
339.58%
Seagen, Inc.
Seagen, Inc.
-0.71%
8.98%
75.48%
18.69%
248.26%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-8.97%
5.01%
10.57%
53.8%
97.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biovie Inc
Biovie Inc
NA
NA
NA
-1.76
-7.48
-1.26
0.0
0.21
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-11.52
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.78
22.78
9.01
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
43.04
43.04
2.03
2.62
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.52
26.52
0.41
15.04
0.23
0.14
0.02
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biovie Inc
Biovie Inc
Buy
$188.1M
-83.18%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$29.6B
329.19%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$87.0B
118.58%
22.78
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$470.4B
339.58%
43.04
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.0B
248.26%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$91.0B
97.36%
26.52
35.94%

Institutional Holdings

  • Ikarian Capital, LLC

    1.24%

  • Vanguard Group Inc

    0.54%

  • Geode Capital Management, LLC

    0.38%

  • BOOTHBAY FUND MANAGEMENT, LLC

    0.27%

  • Moore Capital Management, LP

    0.25%

  • State Street Corporation

    0.24%

Corporate Announcements

  • Biovie Inc Earnings

    Biovie Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

biovie inc. (otc pink: bivi) is developing novel drug therapies for life-threatening complications of chronic liver disease. our initial target is ascites, which can occur in patients with advanced cirrhosis due to hepatitis, nash (non-alcoholic steatohepatitis), or alcoholism. ascites affects about 100,000 americans and carries an estimated 40% mortality rate within two years of being diagnosed. the company’s new drug candidate biv201 is about to enter a phase 2 clinical trial in the us. it’s based on a drug (terlipressin) not yet available in the us, but approved in about 40 countries for treating related complications of liver cirrhosis. the fda has never approved a drug to treat ascites and there is a significant unmet medical need for our novel therapy, which has orphan drug status. biovie has attracted funding from strategic investors including aspire capital, cuong do, the global strategy lead for samsung, and hari kumar, founder of adheron therapeutics which he sold to roche fo

Organization
Biovie Inc
Employees
18
CEO
Mr. Cuong Viet Do M.B.A., MBA
Industry
Biotechnology

Discover More

FAQs